Table 1.
Demographic, clinical and laboratory findings in 35 patients with active PsA and 30 inactive PsA as control group
| Characteristics (Mean ± SD) n (%) | Active PsA) (N = 35) | Inactive PsA (N = 30) | p –value |
|---|---|---|---|
| Age (years) | 44.77± 10.11 | 46.30 ± 12.6 2 | - |
| Gender (male/female) | 20/15 | 17/13 | - |
| Disease duration (years) | 8.18 ± 3.27 | 8.00 ± 2.49 | - |
| BMI (kg/m^2) | 26.42 ± 4.80 | 24.90 ± 4.67 | - |
| Clinical presentations of arthritis, n (%) | - | - | - |
| Low back pain | 13/35 (37.1%) | 8/30 (26.7%) | - |
| Oligoarthritis | 21/35 (60.0%) | 16/30 (53.3%) | - |
| Polyarthritis | 7/35 (20.0%) | 6/30 (20.0%) | - |
| Visual Analogue Scale (VAS) | - | - | - |
| Patient global VAS scores(range 0–100) | 40.57 ± 16.67 | 26.20 ± 7.74 | p<0.05 S |
| Physician global VAS scores(range 0–100) | 29.68 ± 7.53 | 17.19 ± 4.63 | p<0.05 |
| Peripheral joint counts | - | - | - |
| 68 tender joint count (range 0-68) | 42.80 ± 12.80 | 17.93 ± 5.94* | p<0.05 S |
| 66 swollen joint count (range 0-66) | 29.16 ± 3.62 | 17.16 ± 5.06* | p<0.05 S |
| Enthesis/dactylitis counts | - | - | - |
| Leeds Enthesitis Index range 0–6) | 3.28 ± 1.52 | 2.30 ± 0.83* | p<0.05 S |
| Dactylitis count (range 0–20) | 8.94 ± 480 | 6.43 ± 2.40* | p<0.05 S |
| Health-related quality of life and functions: (the mean ± SD), SF36 PCS (range 0–100) | - | - | - |
| 35.11 ± 16.07 | 7.92 ± 6.74* | p<0.05 S | |
| Acute phase reactants | - | - | - |
| ESR (mm/hour) | 42.14 ±16.02 | 8.20 ± 5.67* | p<0.05 S |
| CRP (mg/dl) | 19.08 ± 8.07 | 7.33 ± 6.46* | p<0.05 S |
| PASDAS (the mean ± SD) | 3.50 ± 0.81 | 1.92 ± 0.48* | p<0.05 S |
| US thickness of Plantar fascia (mm) | 4.63 ± 1.16 | 3.62 ± 0.51* | p<0.05 S |
| US thickness of Achilles tendon (mm) | 5.42 ± 1.13 | 4.03 ± 0.36* | p<0.05 S |
| Medications, n (%) | - | - | |
| NSAID | 32/35 (91.4%) | 21/30 (70.0%) | - |
| Methotrexate (7.5–17.5 mg/week) | 30/35 (85.7%) | 20/30 (66.7%) | - |
| Anti-tumor necrosis factor | 4/35 (11.4%) | 2/30 (6.7%) | - |
| Combined therapy | 3/35 (8.6%) | 3/30 (10.0%) | - |
**
p < 0.0001 = highly significant,
*
p<0.05=significant. p>0.05=non-significant (NS). ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PASDAS: Psoriatic Arthritis Disease Activity Score, SF36 PCS: The Short Form 36 Scale (SF-36) health survey -Physical component scale of SF36.